-
December 30, 2021 2021: A Year in Review for the Psychedelics BusinessOur resident Psychedelic Investor looks back at some of this growing industry's biggest moments and...
-
December 29, 2021 Texas Further Embraces Psychedelics with Launch of Center for Psychedelic Research and TherapyResearch will focus on how various psychedelics can be used under proper supervision and guidance...
-
December 28, 2021 Ketamine Rapidly Reduces Depression, According to ‘Most Comprehensive Review’ of Evidence — But Patient Experiences Suggest More ApplicationsPsychedelic Spotlight speaks to a Field Trip Health patient and a psychotherapist, whose experiences suggest...
-
December 27, 2021 Can Psychedelics Treat Alzheimer’s Disease?Since substances such as LSD and psilocybin have powerful anti-inflammatory properties, researchers argue that the...
-
December 24, 2021 Psychedelic Business Spotlight – December 24This week in psychedelic business news: FDA green lights a new psilocybin study; MindMed commences...
-
December 23, 2021 FDA Green Lights Tryp Therapeutics’ Psilocybin Study on Binge Eating DisorderThe pharmaceutical company developing psilocybin-based compounds for diseases with unmet medical needs estimates a $2.9...
-
December 21, 2021 A Second Washington City Approves Decriminalizing PsychedelicsThe psychedelic movement keeps on moving in the Pacific Northwest following Seattle's decriminalization resolution passing...
-
December 16, 2021 Australia Rejects Bid to Reschedule Psilocybin, MDMA for Therapeutic UseMind Medicine Australia, a psychedelics advocacy organization that filed the application, says the country "lost...
-
December 15, 2021 New York Legislator Introduces Bill to Legalize Psilocybin Treatment"Establishing a widespread route to provide New Yorkers with this medical treatment would be a...
-
December 13, 2021 Compass Pathways Study Finds SSRI Drugs Did Not Impede Psilocybin’s Therapeutic EffectChief Medical Officer Guy Goodwin calls study "a strong signal that COMP360 psilocybin therapy could...
